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Objectives: Resection of colorectal cancer (CRC) liver metastases (LM) in pathological liver (PL) patients
(with cirrhosis or hepatopathy) is extremely rare. The aim of this study was to perform a multicentre,
retrospective analysis of epidemiology, surgical techniques and outcomes in patients with PL who
underwent hepatic resection for CRC-LM.
Methods: A retrospective, multicentre questionnaire was distributed to 15 hepatopancreatobiliary sur-
gical units.
Results: Only six of 15 (40%) HPB units reported any experience in the surgical resection of CRC-LM in
patients with PL. Of the 20 patients identified, 10 had underlying cirrhosis and 10 had chronic hepat-
opathy. Their median age was 66 years (range: 49–81 years). Thirteen patients were male. Liver dysfunc-
tion was known preoperatively in 18 patients. All patients had Child–Pugh class A disease. Six patients
had synchronous disease. There were a total of 38 lesions among the 20 patients, distributed at a median
of one lesion per patient (range: 1–4 lesions). The median size of the lesions was 3.0 cm (range:
1.5–9.0 cm). Preoperative median carcinoembryonic antigen (CEA) was 32.3 ng/ml (range: 1–184 ng/ml).
The surgical procedures performed included: sub-segmentectomy (n = 12); left lateral sectionectomy
(n = 6); segmentectomy (n = 4); radiofrequency ablation (n = 3), and exploratory laparotomy (n = 4).
Morbidity occurred in four patients (Clavien grades I [n = 1], II [n = 2] and IVa [n = 1]). Mortality was nil. An
R0 resection margin was achieved in 15 of 16 patients. Twelve patients did not receive chemotherapy. In
resected patients, 10 presented with relapse. The median disease-free and overall survival periods were
12.2 and 22.3 months, respectively.
Conclusions: When feasible, liver resection is the best option for CRC-LM in PL patients.
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Introduction
The incidence of colorectal cancer (CRC) liver metastasis (LM)
within a cirrhotic or pathological liver (PL) is very low.1–5 Many
theories have been proposed in an effort to explain this low rate of
occurrence, including: portal hypertension accompanied by
hepatofugal flows; capillarization of the hepatic parenchyma;
immune alterations; greater levels of matrix metal proteinase
(MMP) inhibitors; tumour necrosis factor-a (TNF-a) or
interferon-a (IFN-a) levels, and the destruction of tumour cellu-
larity by cytotoxic T cells triggered by hepatotropic viruses.1–5 The
number of hepatic resections performed in patients with PL for
CRC-LM is small. Whether this reflects a lack of underlying
hepatic function precluding surgical intervention or whether
there is a significant reduction in the referral of these patients to
liver units for resection is unclear.
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The aim of this study was to perform a multicentre, retrospec-
tive analysis of epidemiology, surgical techniques and outcomes in
patients with PL who underwent hepatic resection for CRC-LM.
Materials and methods
A retrospective, multicentre study was carried out between 1993
and 2009. Fifteen liver surgical units were approached for consul-
tation. All of them replied, but only six had operated for CRC-LM
in patients with PL. Diagnosis was achieved by computed tomog-
raphy scanning. Patients were included in the study on histologi-
cal confirmation of cirrhosis or chronic hepatopathy. No patient
underwent transarterial chemoembolization before a surgical
procedure. The questionnaires distributed to the various centres
asked for epidemiological patient data (age; gender), information
on the hepatopathy (whether or not the origin of the hepatopathy
was known; Child–Pugh score), data on primary tumours
(tumour–node–metastasis [TNM]; type of colon surgery per-
formed), data on LMs (number; sizes), surgical procedures (type
of surgery according to the Brisbane Classification),6 postopera-
tive morbidity and mortality rates collected according to the
Dindo–Clavien classification,7 and relapse rates (localization; type
of treatment performed; total survival and disease-free rates). The
statistical analysis was performed using spss Version 16.0 for Mac
(SPSS, Inc., Chicago, IL, USA). Variables were expressed as median
and range. P-values of <0.05 were considered to indicate statistical
significance.
Results
During the time period studied, a total of 4015 patients under-
went hepatic resection for CRC-LM across all 15 units. Within the
six units that performed hepatic resection for CRC-LM in PL
patients, a total of 2364 (58.9%) patients underwent resection for
CRC-LM. From these six units, 20 patients were identified as
having undergone hepatic resection for CRC-LM in a PL. These
patients represented 0.84% of all CRC-LM subjects resected
across the six units and 0.50% of all liver resections for CRC-LM
carried out across the 15 units surveyed. The 20 patients had a
combined total of 38 liver lesions. Their median age was 66 years
(range: 49–81 years). Thirteen patients were male. The primary
tumour was localized in the colon in 14 patients and in the rectum
in six. The T stage was pT2 (n = 1), pT3 (n = 14) and pT4 (n = 5).
Lymph node involvement was pN0 (n = 10), pN1 (n = 6) and pN2
(n = 4).
Ten of the 20 patients had cirrhosis and 10 had chronic hepat-
opathy. In 18 patients the degree of hepatic dysfunction was
known preoperatively. Causes of hepatopathy included: hepatitis
C virus (HCV) (n = 8); alcohol (n = 4); HCV + HBV infection
(n = 1), and other causes (n = 6). All 10 patients were given
Childs–Pugh A scores.
Six patients had synchronous hepatic disease at the time of
their primary diagnosis. The median number of LMs was one
(range: 1–4). The median size of the lesions was 3.0 cm (range:
1.5–9.0 cm). The median preoperative carcinoembryonic antigen
(CEA) level was 32.3 ng/ml (range: 1–184 ng/ml).
In four patients, exploratory laparotomy was the only proce-
dure performed because the extent of resection required and the
underlying liver disease would have resulted in insufficient liver
remnant in all four cases. Procedures performed in the 16 patients
who underwent resection included 12 sub-segmentectomies, six
left lateral sectionectomies (one laparoscopic), four segmentecto-
mies and three radiofrequency ablations (RFAs). The latter was
employed as a complementary treatment to resection in two
patients (segmentectomy of segment VI and RFA of the lesion on
segment IV; left lateral sectionectomy plus caudate resection and
RFA of the lesion on segment VIII) and as the only treatment in a
lesion concerning segment VIII in one patient. Four patients
developed postoperative complications (Clavien grades I [n = 1],
II [n = 2] and IVa [n = 1]). No patient died in the postoperative
period. An R0 resection was achieved in 15 of the 16 resected
patients.
Postoperatively, one of the four non-resected patients received
further therapy and underwent embolization with irinotecan-
loaded beads. Only four of the 16 patients resected received post-
operative adjuvant therapy. The median follow-up of the 16
patients who underwent resection was 23 months (range: 5–64
months). Ten of the 16 patients developed recurrent disease in the
form of hepatic disease only in four patients, isolated extrahepatic
disease in four patients (pulmonary in three, lymph nodes in one)
and disseminated disease in two patients. Four (three of whom
had undergone resection) of the 20 patients died at 4, 15, 22 and
37 months after surgery, respectively. Median disease-free survival
was 12.2 months and median overall survival was 22.3 months.
The patient treated only with RFA died at 4 months. The other
two RFA patients (RFA + surgery) suffered a hepatic relapse, but
remain alive. The small number of patients treated with RFA does
not permit us to draw conclusions on its efficacy as an exclusive or
complementary treatment in the management of CRC-LM in
patients with PL.
Discussion
Hepatic resection is the most effective treatment in selected
patients with CRC-LM.8 Survival rates at 5 years after resection are
reported to range between 25% and 40% and are currently supe-
rior to those of any other currently available therapeutic option.8
It has previously been observed that few patients with cirrhosis or
hepatopathy accompanied by CRC-LM are referred for surgery.
Several potential reasons for this exist and refer to: a lower inci-
dence of CRC-LM in cirrhotic patients; contraindications to
surgery secondary to significant co-morbidity, and the non-
referral of operable patients.
At present, oncological liver surgery in patients with cirrhosis
can be performed with mortality rates of <5%.9,10 To achieve these
outcomes, a detailed preoperative assessment examining hepatic
function, the presence or absence of portal hypertension, grade of
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cholestasis and remnant liver volume post-resection must be per-
formed.8,9 Resection surgery can be safely performed in a sub-
group of these patients with favourable factors. The extrapolation
of this approach to patients with cirrhosis and CRC-LM allows us
to infer that a proportion of these patients may also undergo
resection.
The perception of a reduced incidence of CRC-LM in PL
patients is based on a series of historic publications – commonly
of autopsies – that reported a low incidence of LM in PLs (cirrho-
sis, fatty liver, etc.) (Table 1).1,2 Many theories have been published
in an attempt to explain why patients with cirrhosis or hepatopa-
thy develop fewer LMs than patients with healthy livers.1–4 So far,
there is no convincing explanation. The most plausible theories
are as follows:
• Mechanical causes: a cirrhotic liver does not represent a breed-
ing ground for the development of tumour cells because fibrosis
and the distortion of small hepatic capillaries which occur in
cirrhosis – known as sinusoid capillarization – represent a
mechanical obstacle to the establishing of tumours.1,2,11
• Immune alterations:1,2 the capillarization mentioned above trig-
gers changes at adhesion molecules and at the hepatic extracel-
lular matrix, which are key points in the metastatic process.11
In addition, the cirrhotic liver shows higher levels of MMP
inhibitors.11
• Hepatofugal flow: a high percentage of cirrhotic patients exhibit
hepatofugal flow, which may favour the non-establishment of
neoplastic cells in the liver. However, this theory is weakened by
the fact that it would suggest a higher number of metastases
on other body organs, an occurrence that has not been
demonstrated.11
• Inferior life expectancy: a lower number of extrahepatic neo-
plasms and fewer LMs caused by these neoplasms are diagnosed
in cirrhotic patients because the life expectancy of such patients
is, in all probability, lowered by the presence of cirrhosis.4,11
• Viral infection: two Japanese series on the frequency of LM in
CRC patients infected with HCV and HBV have resulted in the
proposal of a new theory.1,2 The theory establishes that the rate
of occurrence of LMs is altered by the presence of HBV or HCV
alone, not by the occurrence of hepatic damage, because when
viral replication occurs, the rate of LM is lower, regardless of the
damage on the parenchyma.1,2 According to this theory, viral
infection hinders the development of tumour cells because they
are destroyed by virus-activated cytotoxic T cells when they
reach the hepatic sinusoid. Furthermore, increased production
of IFN-a in patients with HBV and HCV infections may dimin-
ish the occurrence of metastases by stimulating the cytotoxic
capacity of Kupffer cells.2 HBV replication also increases TNF-a
production, which includes an anti-tumour effect.1
In 1999, Seymour and Charny carried out a systematic review of
the literature dealing with postmortem case studies alone, thus
including all published data.11 This 11-study combination con-
cludes that the chances of metastasis occurring are lower in a
cirrhotic liver than in a healthy one, with no differences among
races. A study conducted by Hamaya et al. stands out from the
other case studies included in the review because its authors,
referring to a very large series of autopsies (n = 240 000), express
the discordant view that although the rate of metastasis in non-
cirrhotic livers is higher than that seen in cirrhotic livers,
metastases are not as infrequent as clinical practice suggests.3 The
inherent problem in the information collected by Seymour and
Charny11 is that most of it stems from autopsy studies and, as such,
includes an obvious bias as cirrhotic patients operated on for CRC
exhibit a higher perioperative mortality rate, which means that
patients may become subject to autopsy before they have devel-
oped an LM.11
The current series lends itself to some interesting observations.
It is clear that the frequency of surgery for CRC-LM in patients
with PL is low. At a technical level, the non-resectability rate of
four of 20 patients is higher than the 10% previously published for
hepatopathy-free patients12,13 and in the absence of major hepate-
ctomy.7 These differences reflect the inherent risk of carrying out
major hepatectomies in cirrhotic patients. At present, it appears
that non-anatomic resections are as valid in oncological terms as
anatomic resections.14 The four exploratory laparotomies men-
tioned earlier were conducted in patients with advanced cirrhosis
and thus it seems that patients with chronic hepatopathy are likely
to demonstrate a resectability rate close to that obtained in
hepatopathy-free patients.13 Low morbidity figures and a null
mortality rate represent data similar to those obtained in hepatic
metastasis resections on healthy livers. It is also noteworthy that
hepatic relapses were not managed by re-resection procedures, as
would have been suggested in the case of a healthy liver, but by
chemotherapy or radiofrequency, probably because of a lack of
functional hepatic reserve.15
Table 1 Previous series of liver metastases in pathological livers
Study Cases, n Type of study LM in NL LM in PL Liver disease
Hamaya et al., 19753 240 377 Autopsies 43.2% 26.3% Cirrhosis
Vanbockrijck & Kloppel, 19924 2162 Autopsies 46.4% 33.3% Cirrhosis
Utsunomiya et al., 19992 438 CRC patients 21.2% 8.1% Infection HBV + HCV
Song et al., 20011 512 CRC patients 27.1% 13.5% Infection HBV
Iascone et al., 20055 747 CRC patients 32.0% 4.7% Cirrhosis
LM, liver metastasis; NL, normal liver; PL, pathological liver; CRC, colorectal cancer; HBV, hepatitis B virus; HCV, hepatitis C virus
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The percentage of patients undergoing post-resection chemo-
therapy (25%) is very low compared with that in hepatopathy-free
patients, which ranges from 55% to 75%.12,16 Nevertheless, data on
hepatic relapse (38%) and survival rates are acceptable and similar
to LM series in which chemotherapy rates are higher. As the
current data refer to a retrospective study, the actual reasons for
the low rate of chemotherapy cannot be given, but it is the
authors’ assumption that the hepatopathy was crucial to the deci-
sion not to administer chemotherapy.16 Within the current study,
no difference was detected between the degree of hepatopathy and
survival, but, given the small number of patients, a risk for type II
error exists. Total and disease-free survival rates are similar to
those obtained in hepatopathy-free patients.12
In conclusion, resection of CRC-LM in patients with PL is very
rare. In highly selected patients (patients with chronic hepatopa-
thy or Child–Pugh class A cirrhosis) surgical resection, usually in
the form of minor hepatectomy, can be performed with low mor-
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